2019
DOI: 10.1016/j.eujim.2019.101003
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological mechanism of Astragalus and Angelica in the treatment of idiopathic pulmonary fibrosis based on network pharmacology

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
7
0
3

Year Published

2020
2020
2022
2022

Publication Types

Select...
6

Relationship

4
2

Authors

Journals

citations
Cited by 8 publications
(11 citation statements)
references
References 39 publications
1
7
0
3
Order By: Relevance
“…brevicalyx for wound healing [ 14 ] and A. tmoleus for abdominal pain and toothache [ 15 ]. From the light of these ethnobotanical records, several biological and chemical studies were performed on the members of the genus [ 16 , 17 , 18 , 19 , 20 , 21 , 22 ]. In the chemical studies, some biologically-active compounds, including hyperoside, apigenin, kaempferol, and naringenin, were detected [ 9 ].…”
Section: Introductionmentioning
confidence: 99%
“…brevicalyx for wound healing [ 14 ] and A. tmoleus for abdominal pain and toothache [ 15 ]. From the light of these ethnobotanical records, several biological and chemical studies were performed on the members of the genus [ 16 , 17 , 18 , 19 , 20 , 21 , 22 ]. In the chemical studies, some biologically-active compounds, including hyperoside, apigenin, kaempferol, and naringenin, were detected [ 9 ].…”
Section: Introductionmentioning
confidence: 99%
“…There are many experiments on the treatment of IPF, which manifest RA and RAS can improve pulmonary fibrosis in animal model (Liu, 2009;. Our recent research shows that RA and RAS in the treatment of IPF through the multi-target and multi-pathway were systematically discussed, which plays an important role in the clinical application (Zhang et al, 2019).…”
Section: Introductionmentioning
confidence: 99%
“…At present, there is a wide application of network pharmacology in research related to CHM. It supports the methodology of researching network-based as well as multicomponent therapies, which is compatible with the multipathway, multitarget, and multicomponent features of CHM [25,26].…”
Section: Discussionmentioning
confidence: 77%